Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical progression: requirement of IMV (WHO 7, 8 or 9), 1.2g · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 60 · non‐hospitalised individuals with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab showed no clear difference in mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical progression: oxygen requirement (≥ 5 WHO scale) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab may leads to lower clinical progression: oxygen requirement (≥ 5 WHO scale) compared with placebo (low certainty).
1 finding from 1 review
Clinical progression: IMV or death (≥ 7 WHO scale) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab showed no clear difference in clinical progression: IMV or death (≥ 7 WHO scale) compared with placebo (low certainty).
1 finding from 1 review
Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab may leads to lower admission to hospital or death by day 30 compared with placebo (low certainty).
1 finding from 1 review
Clinical progression/improvement of symptoms · non‐hospitalised individuals with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab may leads to lower adverse events: grades 3 and 4 compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab may leads to lower serious adverse events compared with placebo (low certainty).
1 finding from 1 review